BIOLIFE SOLUTIONS INC (BLFS) research
BIOLIFE SOLUTIONS INC- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Last price
- $37.18
- As of
BIOLIFE SOLUTIONS INC (BLFS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.
As of . Source: SEC EDGAR filings for BLFS. Method and limitations.
Share the BLFS intelligence card
See BLFS live in the terminal
Track BLFS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live BLFS terminal, freeActive signals for BLFS
- highCONSENSUS_BUY
3 tracked funds increased BLFS this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 69% of BLFS (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +2159% to BLFS (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +81% to BLFS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +147% to BLFS (2026Q2)
FREE, NO ACCOUNT
Every signal on BLFS, as it fires
You are seeing 5 of 23 signals recorded on BLFS since 2026-05-29.
The five above landed across 2 days. The other 18 were recorded on 2 other days. 19 of the 23 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BLFS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 09062W204 · 2026Q2 | $17.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 09062W204 · 2026Q2 | $4.5M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 09062W204 · 2026Q2 | $989K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 09062W204 · 2026Q2 | $349K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BLFS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BLFS against its peers
BLFS's operating margin of -17.3% ranks in the 29th percentile of 18 Medical Instruments & Supplies sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | BLFS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 96.2M USD | 86.3M USD | 56 | 16 |
| Gross margin | 64.6% | 54.7% | 85 | 16 |
| Operating margin | -17.3% | 2.6% | 29 | 18 |
| Net margin | -4.8% | -3.2% | 50 | 18 |
| Return on equity | -1.2% | -5.6% | 53 | 17 |
| P / E | n/a | 21.4x | n/a | 5 |
Peers (19): KMTS, AVR, ICUI, STVN, MMED, BLCO, SMTI, EMBC, NNNN, OSUR, UTMD, PDEX, ZJYL, NYXH, KRMD, STXS, ALC, MBOT, NEPH. Left out: AZTA (no annual filing), PLSE (no annual filing), SOAGY (no annual filing), SDMHF (no annual filing), DXR (no annual filing), ZTEK (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (BLFS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more BLFS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BLFSand get the insider, 13F, options, and confluence read in one view.